Natera raised its outlook and emphasized faster prospective study readouts for its Signatera MRD test after reporting a 38% year-over-year jump in Q2 revenue. Executives said booked orders for its Atera spatial biology platform exceeded its full-year shipping expectation, reinforcing demand for MRD-adjacent and broader tumor characterization tools. In parallel, Natera highlighted SIGNAL-ER 101, an interventional study intended to use Signatera to identify HR+/HER2− breast cancer patients for escalation from CDK4/6 inhibitors only when MRD is detected post-surgery. The company framed the program as “practice changing” and outlined a larger SIGNAL portfolio across tumor histologies. Finally, 10x Genomics increased 2026 revenue guidance after customer interest in its Atera spatial biology platform built rapidly, with booked orders already exceeding the prior full-year unit target before shipping constraints limit throughput.